Previous 10 | Next 10 |
Investors have not reacted favorably to phase 2b results of COMPASS Pathways' (CMPS -22.1%) psilocybin treatment for treatment-resistant depression, bringing shares down. Top-line data showed that based on the Montgomery-Asburg Depression Rating Scale ("MADRS"), those who received 25mg of the...
COMPASS Pathways ADS (NASDAQ:CMPS): Q3 GAAP EPS of -$0.38 beats by $0.11. Press Release Cash and cash equivalents were $294.0M as of 30 September 2021, compared with $196.5M at 30 September 2020. For further details see: COMPASS Pathways ADS EPS beats by $0.11
COMPASS Pathways (NASDAQ:CMPS) is trading ~9.2% higher in the pre-market after the company announced that its phase IIb study for COMP360 psilocybin therapy for treatment-resistant depression has reached the primary endpoint for highest 25mg dose. In 233-patient study, a single dose...
LONDON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2021 and g...
Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support COMPASS management team to host an investor conference call today at 1.00pm U...
London, U.K., Nov. 08, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2021, and pr...
Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To Be Wild”, hippie counter-culture illegal drug...
It’s been more than 18 months since Fortune magazine declared “ psychedelic drugs may revolutionize mental healthcare. ” Fortune pointed out how “Silicon Valley legends” and “billionaire financiers” were the main drivers of a ...
London, UK – 3 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be conducting a phase II clinical trial to asse...
Citi analyst Neena Bitritto-Garg says COMPASS Pathways (CMPS +2.9%) and Atai Life Sciences (ATAI +3.1%) are leading a revolution in psychedelic medicines. The pair backed by billionaires including Peter Thiel and German investor Christian Angermayer have dropped in value recently, as shown in...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...